Trial Profile
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary) ; Parsaclisib (Primary) ; Pembrolizumab
- Indications Breast cancer; Colorectal cancer; Ductal carcinoma; Endometrial cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 30 Mar 2022 Status changed from active, no longer recruiting to completed.
- 02 Dec 2020 Planned End Date changed from 29 Sep 2020 to 24 Dec 2021.
- 19 Dec 2019 Planned End Date changed from 1 Mar 2021 to 29 Sep 2020.